Literature DB >> 10821206

Blockade of the serotonergic system counteracts the dizocilpine-induced changes in dopaminergic function.

R Dall'Olio1, O Gandolfi, R Gaggi.   

Abstract

The administration of dizocilpine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist acting at the associated ion channel, increased the grooming time induced in rats by the D1 dopamine receptor agonist SKF 38393 and the stereotyped behaviour elicited by the D1/D2 dopamine receptor agonist apomorphine, and reduced the locomotor response to the D2 dopamine receptor agonist quinpirole. This supports the view that glutamate deficiency plays an important role in the pathogenesis of schizophrenia by altering the balance between glutamatergic and dopaminergic systems. Blockade of serotonin receptors counteracted the effect of dizocilpine on dopaminergic responses. Both the non-selective 5HT1/5HT2 antagonist methysergide, and ketanserin, which more specifically blocks 5HT2 receptors, given at doses inhibiting serotonin-mediated behaviours but which did not affect spontaneous motility and dopaminergic behaviours, hampered the dizocilpine-induced potentiation of responses elicited by the stimulation of D1 or D1/D2 dopamine receptors and counteracted the dizocilpine-induced reduction of hyperactivity observed following quinpirole administration. The results suggest that the functional integrity of the serotonergic system is fundamental for the occurrence of dopaminergic changes resulting from non-competitive NMDA blockade.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10821206     DOI: 10.1097/00008877-200002000-00003

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  4 in total

1.  Superior effects of quetiapine compared with aripiprazole and iloperidone on MK-801-induced olfactory memory impairment in female mice.

Authors:  Ahmet Mutlu; Oguz Mutlu; Guner Ulak; Furuzan Akar; Havva Kaya; Faruk Erden; Pelin Tanyeri
Journal:  Biomed Rep       Date:  2017-03-23

2.  Repeated administration of the novel antipsychotic olanzapine does not modulate NMDA-sensitive glutamate and 5HT2 serotonin receptors in rats.

Authors:  Ottavio Gandolfi; Manuela Voltattorni; Renato Gaggi; Rossella Dall'Olio
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-13       Impact factor: 3.000

3.  Opposing efficacy of group III mGlu receptor activators, LSP1-2111 and AMN082, in animal models of positive symptoms of schizophrenia.

Authors:  Joanna M Wierońska; Katarzyna Stachowicz; Francine Acher; Tomasz Lech; Andrzej Pilc
Journal:  Psychopharmacology (Berl)       Date:  2011-09-28       Impact factor: 4.530

Review 4.  Pharmacology of hallucinations: several mechanisms for one single symptom?

Authors:  Benjamin Rolland; Renaud Jardri; Ali Amad; Pierre Thomas; Olivier Cottencin; Régis Bordet
Journal:  Biomed Res Int       Date:  2014-06-04       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.